Influenza vaccine, adjuvanted quadrivalent and adjuvanted trivalent
Brand: Fluad Quad and Fluad
PBAC's latest decision on Influenza vaccine, adjuvanted quadrivalent and adjuvanted trivalent: Noted (2019). Considered for Active immunisation against influenza in adults aged 65 years and above. The submission sought an increased price premium for Fluad (aTIV) and NIP listing of Fluad Quad (aQIV).
PBAC outcome
Noted
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Adults aged 65 years and above, healthy or with chronic underlying diseases (diabetes, cardiovascular, respiratory), for annual influenza vaccination.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT, Observational
Primary endpoint
Immunogenicity (GMTR, seroconversion rate); hospitalizations for influenza or pneumonia (observational studies)
Pivotal trial size
1,778 patients
Key trials
V118_20, LIVE study (Mannino 2012, Villa 2013), Gravenstein 2018
Comparator
For aTIV (Fluad): non-adjuvanted quadrivalent influenza vaccines (QIVs: Afluria Quad, FluQuadri, Fluarix Tetra). For aQIV (Fluad Quad): aTIV (Fluad) and non-adjuvanted QIV.
Economic model
Cost-minimisation
ICER note
Economic model was cost-minimisation analysis; no ICER with monetary threshold reported. Prices redacted in the PSD.